First study of an anti-Abeta vaccine in people living with Down syndrome (DS)
Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine
Optimized formulation of the ACI-24 vaccine to enter Phase 1b/2 testing this year
LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS.
The landmark study was led by principal investigator Michael Rafii, MD, Ph.D., Professor of Neurology at Keck School of Medicine of the University of Southern California and Medical Director of the Alzheimer’s Therapeutic Research Institute (ATRI). The phase 1b multicenter, placebo-controlled clinical trial was a collaboration between AC Immune, the Alzheimer’s Disease Cooperative Study (ADCS), and clinical investigators at Massachusetts General Hospital, Barrow Neurological Institute and University of California San Diego, with financial support from the National Institute on Aging, part of the National Institutes of Health, and the LuMind IDSC Down Syndrome Foundation.
Dr. Michael Rafii commented: “The data published today in JAMA Neurology demonstrate that interventional clinical trials can be successfully conducted in individuals with Down syndrome. Importantly, the ACI-24 anti-Abeta vaccine was safe, well-tolerated and an anti-Abeta immune response was observed in ACI-24-treated but not placebo-treated participants. As individuals living with DS are at high risk for developing AD-related symptoms by about 55 years of age, a vaccine approach could be particularly relevant.”
Dr. Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer of AC Immune and one of the co-authors of the article, concluded: “The ACI-24 vaccine is derived from our SupraAntigen® platform and designed to generate a polyclonal antibody response targeting pathological forms of Abeta, which following the optimization of its formulation now also includes oligomeric and pyroGlutamate-Abeta. The ensemble of clinical results obtained with ACI-24, encourage us to push the program forward taking the optimized ACI-24 formulation into the next stage of clinical development in both AD and AD in DS in 2022.”
As presented in the JAMA Neurology article, the ACI-24 vaccine demonstrated immunogenicity along with pharmacodynamic and target engagement evidence as measured by a greater increase in plasma Abeta40 and Abeta42 in treated groups compared to placebo. Importantly, anti-Abeta antibody titers were not associated with any adverse findings.
An optimized formulation of ACI-24 has demonstrated strong immunogenicity, inducing a polyclonal response in non-human primates against Abeta and, importantly, high titers of antibodies targeting pyroGlutamate-Abeta (as published in Brain Communications). This neurotoxic species of Abeta found in amyloid plaques is a key driver of disease progression2. Additional data on the optimized formulation were presented at the AD/PD™ 2022, Alzheimer’s & Parkinson’s Diseases Conference held on March 15-20.
References
- Rafii MS et al, Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome, A Phase 1b Randomized Clinical Trial, JAMA Neurology, 2022 May 9:79(5).
- Jawhar S et al, Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease, J Biol Chem. 2011 Nov 11; 286(45).